REGENXBIO (RGNX)
Nasdaq Market Closed
REGENXBIO Inc. is a biotechnology company developing gene therapies intended to treat serious diseases with a genetic or biologic cause. The company’s work is built around its NAV Technology Platform, a collection of adeno-associated virus, or AAV, vectors designed to deliver genetic material into targeted cells. In gene therapy, this delivery mechanism is central: it can be used to replace a faulty gene, add a functional gene, or enable a patient’s cells to produce a therapeutic protein over an extended period.
The company’s internal pipeline is concentrated in areas where one-time or durable therapies could change the treatment model. Its retinal disease programs target conditions that can lead to vision loss, while its neuromuscular and neurodegenerative programs address disorders with limited treatment options and high medical need. REGENXBIO is also known for licensing its NAV vectors to other drug developers, giving the company exposure to partnered gene therapy programs beyond its own research portfolio.
As a clinical-stage biotech, REGENXBIO’s valuation is closely tied to trial progress, regulatory milestones, manufacturing execution, and the broader market appetite for advanced therapies. Its products are investigational, so revenue potential depends on proving safety, durability, and meaningful clinical benefit in patients. The company operates in a competitive gene therapy field, but its focus on AAV delivery technology and a pipeline spanning eye, muscle, and central nervous system diseases gives it a distinct position among specialist genetic medicine developers.
Last updated
- Market Cap
- $721,181,813
- P/E
- —
- P/FCF
- —
- P/S
- 8.21
- Enterprise Value
- $705,952,813
- Sector
- Materials
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNX
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGNX
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $721,181,813
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $705,952,813
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 34.21
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 8.21
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -2.93
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 8.04
- EPS
- -5.61
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$236,403,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -1,375.64%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -84.83%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.62
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.62
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.21
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $2,420,329
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 13.95
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 6.39M | 30.34M | 29.73M | 21.36M | 89.01M |
| Gross profit | -4.68M | 24.41M | 24.01M | 16.15M | 85.58M |
| Operating income | -83.36M | -57.64M | -52.41M | -63.28M | 12.13M |
| EBITDA | -79.51M | -53.77M | -48.53M | -59.37M | 16.08M |
| Net income | -90.05M | -67.15M | -61.94M | -70.87M | 6.08M |
| Basic EPS | -1.72 | -1.3 | -1.2 | -1.38 | 0.12 |
| Diluted EPS | -1.72 | -1.3 | -1.2 | -1.38 | 0.12 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 341.89M | 453.03M | 525.2M | 581.03M | 490.93M |
| Total liabilities | 320.81M | 350.3M | 363.75M | 367.35M | 216.73M |
| Total equity | 21.08M | 102.73M | 161.45M | 213.68M | 274.2M |
| Cash & equivalents | 15.23M | 34.47M | 58.8M | 79.56M | 130.1M |
| Current assets | 186.52M | 281.28M | 331.97M | 373.75M | 313.24M |
| Current liabilities | 71.11M | 118.1M | 124.57M | 119.54M | 106.73M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -76.19M | -52.29M | -55.96M | -49.34M | 33.63M |
| Investing cash flow | 70.59M | 37.54M | 42.29M | -140.44M | 44.74M |
| Financing cash flow | -13.64M | -9.58M | -7.08M | 139.23M | -5.79M |
| Change in cash | -19.24M | -24.34M | -20.76M | -50.55M | 72.58M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SC TO-I/A — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| form 4 | Form 4 — PAKOLA STEVE | View Filing | |
| form 4 | Form 4 — PAKOLA STEVE | View Filing | |
| form 4 | Form 4 — PAKOLA STEVE | View Filing | |
| edgar index | SC TO-I/A — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 144 — REGENXBIO Inc. | View Filing | |
| form 4 | Form 4 — Simpson Curran | View Filing | |
| form 4 | Form 4 — PAKOLA STEVE | View Filing | |
| form 4 | Form 4 — PAKOLA STEVE | View Filing | |
| form 4 | Form 4 — PAKOLA STEVE | View Filing | |
| form 4 | Form 4 — Simpson Curran | View Filing | |
| edgar index | 8-K — REGENXBIO Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — PAKOLA STEVE | View Filing | |
| edgar index | SCHEDULE 13G/A — REGENXBIO Inc. | View Filing | |
| edgar index | 8-K — REGENXBIO Inc. | View Filing | |
| edgar index | SC TO-I — REGENXBIO Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| form 4 | Form 4 — MIGAUSKY GEORGE V | View Filing | |
| form 4 | Form 4 — MIGAUSKY GEORGE V | View Filing | |
| form 4 | Form 4 — KARABELAS ARGERIS N | View Filing | |
| form 4 | Form 4 — KARABELAS ARGERIS N | View Filing | |
| form 4 | Form 4 — STUMP DAVID C | View Filing | |
| form 4 | Form 4 — STUMP DAVID C | View Filing | |
| form 4 | Form 4 — Tasse Daniel | View Filing | |
| form 4 | Form 4 — Tasse Daniel | View Filing | |
| form 4 | Form 4 — Mills Kenneth T. | View Filing | |
| form 4 | Form 4 — Mills Kenneth T. | View Filing | |
| form 4 | Form 4 — Fox Allan M. | View Filing | |
| form 4 | Form 4 — Fox Allan M. | View Filing | |
| form 4 | Form 4 — Fox Allan M. | View Filing | |
| form 4 | Form 4 — Fox Allan M. | View Filing | |
| form 4 | Form 4 — Fox Allan M. | View Filing | |
| form 4 | Form 4 — Fox Allan M. | View Filing | |
| form 4 | Form 4 — Glucksmann Alexandra | View Filing | |
| form 4 | Form 4 — Glucksmann Alexandra | View Filing | |
| form 4 | Form 4 — Zachary Jennifer | View Filing | |
| form 4 | Form 4 — Zachary Jennifer | View Filing | |
| form 4 | Form 4 — Bennett Jean | View Filing | |
| form 4 | Form 4 — Bennett Jean | View Filing | |
| edgar index | 8-K — REGENXBIO Inc. | View Filing | |
| edgar index | 10-Q — REGENXBIO Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | SCHEDULE 13G — REGENXBIO Inc. | View Filing | |
| edgar index | 144 — REGENXBIO Inc. | View Filing | |
| form 4 | Form 4 — PAKOLA STEVE | View Filing | |
| edgar index | DEF 14A — REGENXBIO Inc. | View Filing | |
| edgar index | DEFA14A — REGENXBIO Inc. | View Filing | |
| edgar index | ARS — REGENXBIO Inc. | View Filing | |
| edgar index | PRE 14A — REGENXBIO Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — REGENXBIO Inc. | View Filing | |
| edgar index | 8-K — REGENXBIO Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — REGENXBIO Inc. | View Filing | |
| edgar index | 144 — REGENXBIO Inc. | View Filing | |
| form 4 | Form 4 — PAKOLA STEVE | View Filing | |
| edgar index | 8-K — REGENXBIO Inc. | View Filing | |
| edgar index | 10-K — REGENXBIO Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free